NCT05494229

Brief Summary

Autologous blood for primary and recurrent holes

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 6, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 9, 2022

Completed
23 days until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2023

Completed
Last Updated

March 27, 2023

Status Verified

March 1, 2023

Enrollment Period

6 months

First QC Date

August 6, 2022

Last Update Submit

March 23, 2023

Conditions

Ophthalmopathy

Keywords

Full Thickness Macular HoleBlood ClotWhole bloodPars-pana vitrectomy

Outcome Measures

Primary Outcomes (1)

  • Anatomical outcome

    OCT

    The fourth week post-operatively

Secondary Outcomes (1)

  • Functional outcome

    The fourth week post-operatively.

Study Arms (1)

Utilizing autologous whole blood for the full thickness macular hole

EXPERIMENTAL

It is an interventional study by performing pars-plana vitrectomy

Other: Pars-plana vitrectomy

Interventions

Pars-plana vitrectomyOTHER

Pars-plana vitrectomy

Utilizing autologous whole blood for the full thickness macular hole

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Primary and recurrent holes

You may not qualify if:

  • Lamellar and pseudoholes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Omer Othman Abdullah

Erbil, 44001, Iraq

Location

MeSH Terms

Conditions

Eye DiseasesThrombosis

Condition Hierarchy (Ancestors)

Embolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Officials

  • Omer Abdullah, M.Sc.

    Ibinsina Modern Eye and Retina Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate consultant ophthalmologist

Study Record Dates

First Submitted

August 6, 2022

First Posted

August 9, 2022

Study Start

September 1, 2022

Primary Completion

March 1, 2023

Study Completion

March 1, 2023

Last Updated

March 27, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations

IR(1)